Positive News SentimentPositive NewsNASDAQ:ANNX Annexon (ANNX) Stock Price, News & Analysis $2.18 +0.15 (+7.39%) Closing price 04:00 PM EasternExtended Trading$2.18 +0.00 (+0.23%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Annexon Stock (NASDAQ:ANNX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Annexon alerts:Sign Up Key Stats Today's Range$2.01▼$2.2150-Day Range$1.38▼$2.7052-Week Range$1.29▼$7.85Volume825,196 shsAverage Volume1.78 million shsMarket Capitalization$239.18 millionP/E RatioN/ADividend YieldN/APrice Target$12.50Consensus RatingBuy Company OverviewAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Read More… Annexon Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreANNX MarketRank™: Annexon scored higher than 42% of companies evaluated by MarketBeat, and ranked 686th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAnnexon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnnexon has only been the subject of 2 research reports in the past 90 days.Read more about Annexon's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Annexon are expected to decrease in the coming year, from ($0.96) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annexon is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annexon is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnnexon has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Annexon's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.88% of the float of Annexon has been sold short.Short Interest Ratio / Days to CoverAnnexon has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Annexon has recently increased by 9.28%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnnexon does not currently pay a dividend.Dividend GrowthAnnexon does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.88% of the float of Annexon has been sold short.Short Interest Ratio / Days to CoverAnnexon has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Annexon has recently increased by 9.28%, indicating that investor sentiment is decreasing significantly. News and Social Media3.7 / 5News Sentiment1.73 News SentimentAnnexon has a news sentiment score of 1.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Annexon this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for ANNX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Annexon to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Annexon insiders have not sold or bought any company stock.Percentage Held by Insiders11.87% of the stock of Annexon is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Annexon's insider trading history. Receive ANNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annexon and its competitors with MarketBeat's FREE daily newsletter. Email Address ANNX Stock News HeadlinesAnnexon Biosciences to Present at the Jefferies Global Healthcare ConferenceMay 29 at 4:05 PM | globenewswire.comAnnexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual MeetingMay 19, 2025 | globenewswire.comIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.May 29, 2025 | Colonial Metals (Ad)Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)May 16, 2025 | globenewswire.comCantor Fitzgerald maintains Overweight on Annexon stockMay 14, 2025 | investing.comAnnexon, Inc. Announces Upcoming FDA Meeting and Progress on Novel Therapies for Neurological and Ophthalmic DiseasesMay 13, 2025 | nasdaq.comAnnexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated MilestonesMay 12, 2025 | globenewswire.comAnnexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS MeetingMay 9, 2025 | globenewswire.comSee More Headlines ANNX Stock Analysis - Frequently Asked Questions How have ANNX shares performed this year? Annexon's stock was trading at $5.13 at the beginning of 2025. Since then, ANNX shares have decreased by 57.5% and is now trading at $2.18. View the best growth stocks for 2025 here. How were Annexon's earnings last quarter? Annexon, Inc. (NASDAQ:ANNX) announced its earnings results on Monday, May, 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.07. When did Annexon IPO? Annexon (ANNX) raised $150 million in an IPO on Friday, July 24th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen acted as the underwriters for the IPO. Who are Annexon's major shareholders? Top institutional investors of Annexon include Woodline Partners LP (1.93%), Goldman Sachs Group Inc. (0.77%), Walleye Capital LLC (0.73%) and Charles Schwab Investment Management Inc. (0.66%). Insiders that own company stock include Bain Capital Life Sciences Inv, Douglas Love, Michael Overdorf, Dean Richard Artis, Jennifer Lew, Ted Yednock, Jamie Dananberg and William H Carson. View institutional ownership trends. How do I buy shares of Annexon? Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Annexon own? Based on aggregate information from My MarketBeat watchlists, some other companies that Annexon investors own include NVIDIA (NVDA), MercadoLibre (MELI), Advanced Micro Devices (AMD), Meta Platforms (META), CRISPR Therapeutics (CRSP) and Energy Transfer (ET). Company Calendar Last Earnings5/12/2025Today5/29/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANNX CIK1528115 Webwww.annexonbio.com Phone650-822-5500Fax650-636-9773Employees60Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$14.00 Low Stock Price Target$11.00 Potential Upside/Downside+473.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$134.24 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.99% Return on Assets-33.90% Debt Debt-to-Equity RatioN/A Current Ratio17.17 Quick Ratio17.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.20 per share Price / Book0.68Miscellaneous Outstanding Shares109,714,000Free Float93,089,000Market Cap$239.18 million OptionableOptionable Beta1.24 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ANNX) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.